a b s t r a c t DNA damage checkpoints are essential for maintenance of genome integrity. We report here that inducible overexpression of the transcription factor Sharp-1 results in an S and G2/M cell cycle arrest, concomitant with the upregulation of Brca1 and GADD45a expression. In addition, we show that endogenous Sharp-1 mRNA is increased by DNA-damaging agents. Consistently, Sharp-1 overexpressing cells exhibit reduced apoptosis in response to chemotherapeutic drugs along with lower p53 expression and activity. Our studies identify a novel function for Sharp-1 in cell cycle arrest and DNA damage-induced apoptosis. Inappropriate Sharp-1 expression may therefore be associated with tumorigenesis.
Introduction
Genome integrity is dependent on the activation of checkpoints that block cell cycle progression [1] [2] [3] [4] [5] . In response to cellular stress such as DNA damage, mammalian cells arrest in the G1, S, or G2/M phase that allows them to repair DNA. The G2 checkpoint plays a pivotal role in this process by inhibiting the entry of cells harboring DNA damage into mitosis. If the damage cannot be repaired, programmed cell death (apoptosis) is initiated to eliminate genetically altered cells from the proliferative pool. The tumor suppressor p53 plays a key role in the DNA-damage response. In addition to its established role in G1 arrest through regulation of p21 cip1/waf1 expression, p53 plays a role in G2/M arrest through regulation of GADD45a, 14-3-3, and cyclin B1 [5] . p53 also regulates the expression of genes required for apoptosis which include Puma, Noxa and Bax [6, 7] . A failure of this surveillance response results in genetic alterations that lead to genome instability and development of cancers, immunodeficiency, neurodegenerative diseases, and premature ageing [1] [2] [3] [4] [5] .
We have previously demonstrated that the transcription factor Sharp-1/Dec2 is widely expressed, and plays key roles in cellular differentiation [8] [9] [10] . The hitherto unstudied role of Sharp-1 in regulation of cellular growth arrest and apoptosis are addressed in this present report. We demonstrate that endogenous Sharp-1 mRNA is up-regulated by genotoxic agents, and its overexpression results in S and G2/M cell cycle arrest. Sharp-1 upregulates the expression of Brca1 and GADD45a, that control cell cycle arrest and DNA repair [11, 12] . Consistent with its ability to block cell cycle progression, Sharp-1 overexpressing cells exhibit an abrogated apoptotic response in presence of DNA damaging triggers and express reduced levels of p53 and its transcriptional targets. Together, our studies demonstrate that Sharp-1 plays a key role in protection of cells from anti-cancer drugs, and suggest that its altered function or expression may be associated with tumorigenesis and or tumor progression.
Materials and methods

Cell culture
Doxycycline inducible Sharp-1 expressing cell lines were generated using the rtTA inducible system. NIH3T3 fibroblast cells (ATCC) were transfected with EF1prtTA [13] and selected with G418. After selection, cells were co-transfected with myc-tagged Sharp-1 in pUHD10-3 and a puromycin resistance vector [14] . Individual colonies were analyzed for Sharp-1 expression in response to doxycycline (2 lg/ml). Cells containing both vectors but not induced with doxycycline were used as controls. Cells were cultured in DMEM supplemented with 10% bovine serum. 
Colony formation assay
Colony formation assays were done as described [14] . Colonies were stained with crystal violet. The dye was extracted and the absorbance read at 570 nm.
Cell cycle analysis
Cell cycle analysis was done as described [14] . Flow cytometry was performed in a BD Coulter flow cytometer and analyzed using WINMDI software. 
Caspase-3 activity
Caspase-3 activity assays were based on cleavage of the substrate Ac-DEVD-pNA [Biomol International]. Cleavage of the substrate was measured spectrophotometrically at 405 nm and the activity calculated.
Reverse transcriptase PCR (RT-PCR)
Semi-quantitative, and quantitative RT-PCR was done as described [10, 15] . Primers sequences are listed in Supplementary Table 1.
Statistical analysis
Error bars indicate means ± standard error (S.E.). Statistical analysis was performed by Student's t-test and P values < 0.05 were considered statistically significant.
Results and discussion
Sharp-1 causes growth arrest
To investigate the role of Sharp-1 in growth arrest and apoptosis, we established stable cell lines in NIH3T3 cells that express myc-tagged Sharp-1 in a doxycycline inducible manner. Cells containing the Sharp-1 construct, but not induced with doxycycline, were used as controls. To examine the kinetics of Sharp-1 induction, cells were left untreated (time 0) or treated with doxycycline for various time points and analyzed by Western blot analysis. In the absence of doxycycline, Sharp-1 expression was not detectable using anti-myc antibody (Fig. 1A, time 0 h ). Treatment of cells with doxycycline resulted in the induction of Sharp-1 within 8 h, which was apparent until 72 h (Fig. 1A) . Immunofluorescence analysis indicated that Sharp-1 was localized in the nucleus (Fig. 1A, lower panel) . Compared to control cells, the induction of Sharp-1 expression resulted in a significant reduction of cell numbers (Fig. 1B) . To confirm the growth inhibitory effect of Sharp-1, colony formation assays were performed. NIH3T3 cells were cultured in the absence or presence of doxycycline and colony formation was visualized by crystal violet staining (Fig. 1C,  left panel) . Sharp-1 expression resulted significant decrease in colony numbers compared to control cells (Fig. 1C, right panel) .
Together, these results demonstrate that Sharp-1 is a potent growth suppressor. To investigate whether Sharp-1 mediated growth suppression is due to an effect on the cell cycle, or on apoptosis, we first performed cell cycle analysis (Fig. 1D) . Interestingly, 24 h after induction of Sharp-1, a significant increase in the percentage of cells in the S and G2/M phases was evident, with no obvious increase in the sub-G1 population (Fig. 1D, left  panel) .
We then analyzed the mechanisms underlying growth arrest induced by Sharp-1. The G2/M checkpoint is controlled by the cyclin B/Cdc2 complex. Compared to control cells, cyclin B1 expression was somewhat increased after induction of Sharp-1, whereas the levels of p-cdc2-Tyr15, which inhibits cyclin B/ Cdc2 activity [16] remained unchanged ( Fig. 2A) . Moreover, no changes in the levels of p21 and Cdk2 were apparent. However, p53 levels were increased 36 h after Sharp-1 expression compared to control cells. One of the key p53 target genes involved in G2/M arrest is GADD45a [11] . In control cells, GADD45a was slightly increased over time. Interestingly, GADD45a mRNA was up-regulated by Sharp-1 even prior to the induction of p53, indicating that GADD45a may be directly regulated by Sharp-1 (Fig. 2B) . Similarly, Brca1, which is required for S-phase arrest and DNA-repair was induced by Sharp-1 (Fig. 2B) . A hallmark of entry into mitosis is the phosphorylation of histone H3 [17] . In control cells, histone H3 phosphorylation (ser 10) was increased at 16 h (Fig. 2C) . In contrast, Sharp-1 overexpressing cells showed a marked reduction in phospho H3 levels confirming that Sharp-1 disrupts G2 progression. Given the S-phase arrest induced by Sharp-1, we further examined genes involved in DNA-replication or repair [1] [2] [3] [4] [5] 12] . However, the expression of RPA, 53BP1, MDC1 and PCNA was not altered by Sharp-1 overexpression ( Fig. 2D and E) .
Sharp-1 is induced by genotoxic agents and protects cells from apoptosis
The DNA-damage pathway activates the G2/M checkpoint, which provides a survival mechanism in mammalian cells [18] . Since Sharp-1 expression results in a pronounced G2/M arrest, we investigated its role in the DNA-damage response. We first analyzed whether Sharp-1 expression is modulated by DNA damage. NIH3T3 cells were treated with the anti-cancer drugs 5-FU, cisplatin, and etoposide ( Fig. 3A and B) . Interestingly, similar to GADD45a, Sharp-1 mRNA was elevated by all genotoxic stimuli (Fig. 3A, left panel and B) suggesting that it may modulate the cellular response to chemotherapeutic drugs. Sharp-1 expression however, was not increased by prolonged culture in the absence of drug treatment (Fig. 3A, right panel) .
Since Sharp-1 is up-regulated by genotoxic agents and triggers arrest, we hypothesized that Sharp-1 expression may favor cell survival in face of DNA damage. We therefore examined the effect of Sharp-1 on DNA-damage-induced apoptosis. Sharp-1 was induced with doxycycline for 8 h, and cells were then treated with 5-FU or cisplatin. The extent of apoptosis was assayed by flow cytometry using the sub-G1 fraction as a surrogate marker. In control cells treated with 12.5 lM or 25 lM 5-FU alone, 27% and 30% of cells underwent apoptosis, respectively. In Sharp-1 overexpressing cells however, apoptosis was significantly reduced to 16% and 18%, respectively ( Fig. 3C and D) . Similar effects were seen with cisplatin treatment (Supplementary Fig. 1 ). Consistent with the above results, Sharp-1 overexpressing cells exhibited a significant decrease in caspase-3 activity in response to 5-FU compared to control cells (Fig. 3E) . Moreover, compared to control cells, Sharp-1 overexpressing cells showed a striking reduction of the mitotic marker phospho-histone H3 (Fig. 3F) , confirming that the cells are arrested in the G2 phase.
Sharp-1 attenuates the p53 response to DNA damage
Activation of the p53 pathway is essential for the response to DNA damage. To study the mechanisms underlying apoptosisresistance conferred by Sharp-1, we analyzed p53 expression levels and its transcriptional activity. NIH3T3 cells were pre-treated with doxycycline for 16 h to induce Sharp-1 expression. Cells were then co-treated with 5-FU for 0, 3, 8 and 24 h. Sharp-1 was expressed for the duration of drug treatment (Fig. 4A) . In control cells, p53 was significantly up-regulated as early as 3 h (Fig. 4B) . In contrast, the p53 response was attenuated three and 8 h after 5-FU treatment in Sharp-1 expressing cells, although at late stages there was no obvious difference. Concomitantly the expression of p21 waf1/cip1 and Bax was reduced suggesting that p53 transcriptional activity is attenuated by Sharp-1 expression. In contrast, Bcl2 levels were increased in Sharp-1 overexpressing cells.
To further examine p53 activity, we analyzed the mRNA levels of several p53 target genes (Fig. 4C) . Consistent with reduced apoptosis and p53 levels, the expression of Puma, Noxa, Bax, and Stra13/Dec1 [6, 7, 15] were not appropriately induced by 5-FU in Sharp-1 overexpressing cells. In contrast, GADD45a was elevated compared to control cells at early time points and not induced further. It is noteworthy that Sharp-1 expression alone is sufficient to down regulate Bax and Stra13 expression even in the absence of 5-FU, and upregulate GADD45a levels ( Figs. 2  and 4 ; time 0, +doxycycline). On the other hand, the reduced expression of Puma and Noxa may be due to reduced p53 activity as the expression of these genes is not altered by Sharp-1 alone. We have previously reported that Stra13 is repressed by Sharp-1, and regulates DNA-damage-induced apoptosis [9, 15] . Consistent with these studies Stra13 is down-regulated in Sharp-1 expressing cells that are resistant to apoptosis. Similar to the responses seen with 5-FU, Sharp-1 overexpressing cells also showed reduced levels of p53, p21 and Bax in response to cisplatin (data not shown). Taken together, our studies indicate a novel regulatory axis through which Sharp-1 regulates survival of normal cells via activation of cell cycle checkpoints. This function provides protection from the cytotoxic effects of DNA damaging agents. This survival mechanism is applicable to normal cells (this study). It is conceivable that inappropriate Sharp-1 expression plays a role tumorigen- esis and/or tumor progression and other disorders such as premature ageing arising from cell survival subsequent to DNA damage.
